Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993106 · ClinicalTrials.gov registry record · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
A Phase 2 study of Kaposi Sarcoma, sponsored by Vasgene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 3
- Study locations
NCT03993106 is a Phase 2 study of Kaposi Sarcoma that is actively recruiting participants, run by Vasgene Therapeutics. The registered enrollment target is 65 participants, below the 97-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03993106, a Phase 2 study of Kaposi Sarcoma, is actively recruiting participants, sponsored by Vasgene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 3
- Study locations
Study Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Conditions Studied
Interventions
- DRUG sEphB4-HSA
Study Locations (3)
California
- AIDS Healthcare Foundation - Beverly Hills
Florida
- CAN (Community AIDS Network) Community Health - Sarasota
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993106
The ClinicalTrials.gov registry entry for NCT03993106 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (33% lower). The listed sponsor is Vasgene Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which sEphB4-HSA is the first listed.
NCT03993106 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03993106 about?
NCT03993106 is a clinical study titled "A Study of sEphB4-HSA in Kaposi Sarcoma". sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
What is the current status of trial NCT03993106?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-09-17. Estimated completion is 2025-06.
What conditions does trial NCT03993106 study?
This clinical trial studies the following conditions: Kaposi Sarcoma.
What interventions are being tested in trial NCT03993106?
The interventions under investigation include: sEphB4-HSA (DRUG).
Who is sponsoring clinical trial NCT03993106?
This trial is sponsored by Vasgene Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993106 being conducted?
This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
-
Propranolol for the Treatment of Kaposi Sarcoma in Adults
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.